OGXI Insider Trading Activity and SEC Form 4 Filings
OGXI insider trading summary
No open-market insider purchases or sales of Oncogenex Pharmaceuticals, Inc. (OGXI) have been reported on SEC Form 4 in the past 12 months.
Latest OGXI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 19, 2016 | John Bencich | CFO | Sell | $787 (1,380 @ $0.57) |
| Jun 13, 2016 | Scott Daniel Cormack | President and CEO | Sell | $5K (4,856 @ $1.03) |
| Jun 13, 2016 | Cindy Jacobs | EVP, CMO | Sell | $1K (1,437 @ $1.03) |
| Mar 15, 2016 | John Bencich | CFO | Sell | $692 (834 @ $0.83) |
| Mar 15, 2016 | Cindy Jacobs | EVP, CMO | Sell | $3K (3,254 @ $0.83) |
| Mar 15, 2016 | Scott Daniel Cormack | President and CEO | Sell | $10K (12,033 @ $0.83) |
| Aug 18, 2015 | John Bencich | CFO | Sell | $4K (1,427 @ $2.76) |
| Jun 12, 2015 | Scott Daniel Cormack | President and CEO | Sell | $12K (4,571 @ $2.69) |
| Jun 12, 2015 | Cindy Jacobs | EVP, CMO | Sell | $4K (1,408 @ $2.69) |
| May 20, 2015 | Cindy Jacobs | EVP, CMO | Sell | $4K (2,092 @ $1.88) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.